Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hypoxia response elements (HREs) are short, conserved DNA sequences (often with the consensus core: 5'-RCGTG-3', e.g., 5'-CGTG-3') located in the promoters/enhancers of hypoxia-inducible genes[2][7][9]. They enable binding of the HIF-1 transcription factor complex, which is a heterodimer of the oxygen-regulated HIF-1α and the constitutively expressed HIF-1β (ARNT)[1][2][7]. Under low oxygen, HIF-1α stabilizes, partners with HIF-1β, and the complex binds to HREs, increasing transcription of genes such as VEGF (angiogenesis), erythropoietin (erythropoiesis), glycolytic enzymes, and others essential for cellular adaptation to hypoxia[7][5][9]. HREs themselves are not protein targets, but rather genomic motifs recognized by HIF-1 and related factors, making them crucial for understanding hypoxic gene regulation but inappropriate as direct therapeutic targets[2][5][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hypoxia response element (HRE).